Patients recruited to this Pilot study will have the whole genome of the tumor and cells sequenced and data stored in database.  Treatment, demographic and clinical outcomes data will be collected and then clinical outcomes followed up for a minimum of 3 years (or until death) and correlated with the molecular profiles generated. The whole genome sequencing (WGS) data generated will allow classification into both prognostic risk groups and also potentially identify molecular drivers of breast cancer (e.g. CCND1, PAK1, ERBB2) and molecular profiles predictive of treatment response or non-response. We will store the RNA during the lifetime of the study from the patients where genome is sequenced, and we will explore the feasibility of including these results in clinical reports at a later stage. We will also investigate mutation signatures associated with prediction of treatment response to chemotherapy and also targeted agents.

This will be a single-centre study in Tata Medical Center, Kolkata with a sample size of 200 patients with breast cancer. Patients will be followed-up for a minimum of 5 years (or until death) from the date they receive their genomic results.

The primary objective is to evaluate the clinical feasibility and clinical utility of Whole Genome Sequencing (WGS) in the clinical management of breast cancer patient, in real world setting